STIOLTO RESPIMAT: payments to doctors
Payments that named STIOLTO RESPIMAT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $3M
- Providers
- 35,430
- Transactions
- 142,560
- Average per transaction
- $21
The per-transaction average — $21 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 35,430 providers the average total is $86, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $2,923,329 | 96.1% |
| Boehringer Ingelheim International GmbH | $44,144 | 1.5% |
| Boehringer Ingelheim Mexico SA De CV | $25,272 | 0.8% |
| Boehringer Ingelheim Hong Kong Ltd | $16,315 | 0.5% |
| Boehringer Ingelheim Singapore Pte. Ltd. | $11,874 | 0.4% |
| Boehringer Ingelheim Malaysia Sdn. Bhd. | $7,187 | 0.2% |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | $4,580 | 0.2% |
| Boehringer Ingelheim Korea LTD. | $3,000 | 0.1% |
| Boehringer Ingelheim S.A. | $2,705 | 0.1% |
| Boehringer Ingelheim Hong Kong Ltd. | $2,500 | 0.1% |
| Boehringer Ingelheim Pty Ltd | $1,935 | 0.1% |
| Boehringer Ingelheim Taiwan Ltd. | $520 | 0.0% |